| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 336 | 2019 |
| Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow … I Yakoub-Agha, C Chabannon, P Bader, GW Basak, H Bonig, F Ciceri, ... haematologica 105 (2), 297, 2020 | 252 | 2020 |
| Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the … PJ Hayden, C Roddie, P Bader, GW Basak, H Bonig, C Bonini, ... Annals of Oncology 33 (3), 259-275, 2022 | 175 | 2022 |
| Bortezomib for the treatment of multiple myeloma K Scott, PJ Hayden, A Will, K Wheatley, I Coyne Cochrane Database of Systematic Reviews, 2016 | 161 | 2016 |
| Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 DW McMillin, M Ooi, J Delmore, J Negri, P Hayden, N Mitsiades, ... Cancer research 69 (14), 5835-5842, 2009 | 154 | 2009 |
| Strategems in Vitro for Gene Therapies Directed to Dominant Mutations S Millington-Ward, B O'Neill, G Tuohy, N Al-Jandal, AS Kiang, PF Kenna, ... Human Molecular Genetics 6 (9), 1415-1426, 1997 | 109 | 1997 |
| Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage C Fernández de Larrea, R Kyle, L Rosiñol, B Paiva, M Engelhardt, ... Blood cancer journal 11 (12), 192, 2021 | 84 | 2021 |
| Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib MG Ooi, PJ Hayden, V Kotoula, DW McMillin, E Charalambous, ... Clinical Cancer Research 15 (23), 7153-7160, 2009 | 82 | 2009 |
| Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling MS Raab, I Breitkreutz, G Tonon, J Zhang, PJ Hayden, T Nguyen, ... Blood, The Journal of the American Society of Hematology 113 (7), 1513-1521, 2009 | 80 | 2009 |
| GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo MS Raab, I Breitkreutz, S Anderhub, MH Rønnest, B Leber, TO Larsen, ... Cancer research 72 (20), 5374-5385, 2012 | 78 | 2012 |
| From the bench to the bedside: emerging new treatments in multiple myeloma CS Mitsiades, PJ Hayden, KC Anderson, PG Richardson Best practice & research Clinical haematology 20 (4), 797-816, 2007 | 78 | 2007 |
| Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working … D McLornan, R Szydlo, L Koster, Y Chalandon, M Robin, C Wolschke, ... Biology of Blood and Marrow Transplantation 25 (11), 2167-2171, 2019 | 77 | 2019 |
| Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma PJ Hayden, P Tewari, DW Morris, A Staines, D Crowley, A Nieters, ... Human molecular genetics 16 (24), 3117-3127, 2007 | 71 | 2007 |
| A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase PJ Hayden, F Keogh, M Ni Conghaile, M Carroll, M Crowley, N Fitzsimon, ... Bone marrow transplantation 34 (6), 545-556, 2004 | 56 | 2004 |
| UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high‐dose chemoradiotherapy for patients with malignancy KW Douglas, M Gilleece, P Hayden, H Hunter, PRE Johnson, ... Journal of clinical apheresis 33 (1), 46-59, 2018 | 52 | 2018 |
| Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies … N Polverelli, K Mauff, N Kröger, M Robin, D Beelen, D Beauvais, ... American journal of hematology 96 (1), 69-79, 2021 | 46 | 2021 |
| Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best … DP McLornan, JC Hernandez-Boluda, T Czerw, N Cross, ... Leukemia 35 (9), 2445-2459, 2021 | 41 | 2021 |
| Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen, J Passweg, ... Leukemia 35 (12), 3551-3560, 2021 | 39 | 2021 |
| An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT PJ Hayden, T Sirait, L Koster, JA Snowden, I Yakoub-Agha Current Research in Translational Medicine 67 (3), 79-88, 2019 | 39 | 2019 |
| PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells EN Maginn, PV Browne, P Hayden, E Vandenberghe, B MacDonagh, ... British journal of cancer 104 (2), 281-289, 2011 | 36 | 2011 |
